On Demand 2017 Monday General Sessions

This collection covers general sessions from Monday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Current Approaches for Treatment of Obstructive Lung Disease
  • What We Know: Non-infectious Complications of PID
  • Immunology of Eczema: How to Best Address the Itch that Rashes Cause

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Evaluate the potential positive outcomes from GINA add-on therapy.
  • Choose the patient population that will not have sufficient burden of disease to necessitate GOLD therapy.
  • Evaluate all of the evidence to provide guidance for appropriate cost-effective use of these medications.
  • Demonstrate competency in recognizing various forms of dermatitis that are not eczema.
  • Apply treatment strategies to relieve symptoms of dermatitis.
  • Prioritize different treatment strategies for the patient who itches from dermatitis.
  • Describe the frequency of non-infectious complications of primary immunodeficiency.
  • Recognize the manifestations of non-infectious complications of primary immunodeficiency and the appropriate evaluation of the patient.
  • Be aware of the therapeutic options available for the treatment of monogeneic immunodeficiencies, including monoclonal antibodies.

 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2017 Annual Meeting is conveniently located online at college.acaai.org/disclosures. There is a link to this information in the Annual Meeting app under Disclosures.

Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Attendance
  • 2.50 MOC
Course opens: 
10/30/2017
Course expires: 
10/30/2020
Part of: 
2017 ACAAI Annual Meeting On Demand: General Sessions
Rating: 
0
  • Lynda Schneider, MD, FACAAI
  • Donald Y. Leung, MD, PhD, FACAAI
  • Gil Yosipovitch, MD
  • Luz S. Fonacier, MD, FACAAI
  • Richard L. Wasserman, MD, PhD, FACAAI
  • Kathleen Sullivan, MD, PhD
  • Troy Torgersen, MD, PhD
  • Jennifer Leiding, MD

Available Credit

  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Attendance
  • 2.50 MOC
Please login or create an account to take this course.